Abstract: The invention relates to a substitution infusion fluid for hemofiltration of a specific composition. The use of said substitution infusion fluid significantly reduces the risk of the occurrence of abnormalities in a patient undergoing pure hemofiltration. The invention also relates to process for pure hemofiltration of blood wherein said substitution infusion fluid is used. The invention also relates to a matching citrate anticoagulation fluid of a specific composition. The invention also relates to a process for pure hemofiltration of blood wherein said substitution infusion fluid is used in combination with said citrate anticoagulation fluid. The use of said substitution infusion fluid in combination with said citrate anticoagulation fluid significantly further reduces the risk of the occurrence of abnormalities in a patient undergoing pure hemofiltration.

Abstract: A nonallergenic synthetic rubber elastomer having physical qualities equal to or superior to natural rubber latex is provided. The synthetic rubber elastomer is composed of at least one high molecular weight hydrogenated tri-block thermoplastic elastomer (HTPE), at least one low molecular weight HTPE and a crosslinkable cyclic unsaturated polyolefin crystalline polymer. Articles are formed from the synthetic rubber elastomers and then exposed to crosslinking agents. The articles thus formed possess physical qualities equal to or superior to natural rubber latex and improved biocompatability.

Abstract: The present invention provides functionally modified thermoplastic elastomeric compounds composed of at least one polystyrene hard domain, at least one polyolefin rubber domain and at least one cross-linkable compound interspersed within one or more of the domains. Methods for making and using these thermoplastic elastomeric compounds are also provided as are articles made from these compounds along with methods for making such articles.

Abstract: Methods and compositions are provided for producing recombinant AAV vector particles; comprising the general steps of (a) introducing into a host cell (i) pfloxAAV, (ii) a recombinant viral vector encoding plasmid, and (iii) a plasmid encoding herpesvirus, cytomegalovirus, or adenoviral functions, or a herpesvirus, cytomegalovirus, or, adenovirus itself, in order to produce flox AAV particles and recombinant AAV particles; and (b) introducing into a second host cell (i) the recombinant AAV particles and flox AAV particles of (a), (ii) a vector which directs the expression of Cre, and (iii) a vector which directs the expression of herpesvirus, CMV, or adenovirus helper functions, such that said recombinant AAV vector particles are produced.